Goldfarb Melanie, Singer Frederick R
Center for Endocrine Tumors and Disorders, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, 90404, USA.
Endocrine/Bone Disease Program, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, 90404, USA.
F1000Res. 2020 Feb 25;9. doi: 10.12688/f1000research.21569.1. eCollection 2020.
Primary hyperparathyroidism is a hormonal disorder whose prevalence is approximately 1-2% in the United States of America. The disease has become more recognizable to clinicians in an earlier phase and, at present, patients can be diagnosed with "classic", "normocalcemic", "normohormonal", or "mild, asymptomatic" primary hyperparathyroidism. Surgery, with a focused parathyroidectomy when possible, or a four-gland exploration, is the only way to cure the disease. Cure is determined by use of intra-operative parathyroid hormone monitoring with long-term cure rates ranging from 90-95%. Newer adjuncts to surgery include CT or PET imaging and near-infrared immunofluorescence. This article highlights updates in parathyroid disease and advances in parathyroid surgery; it does not provide a comprehensive summary of the disease process or a review of surgical indications, which can be found in the AAES guidelines or NIH Symposium on primary hyperparathyroidism.
原发性甲状旁腺功能亢进是一种激素紊乱疾病，在美国其患病率约为1%-2%。该疾病在临床医生中已更容易在早期阶段被识别，目前患者可被诊断为“经典型”“血钙正常型”“激素水平正常型”或“轻度、无症状型”原发性甲状旁腺功能亢进。手术，尽可能进行有针对性的甲状旁腺切除术或探查四个甲状旁腺，是治愈该疾病的唯一方法。治愈通过术中甲状旁腺激素监测来确定，长期治愈率为90%-95%。手术的新辅助手段包括CT或PET成像以及近红外免疫荧光。本文重点介绍甲状旁腺疾病的最新进展和甲状旁腺手术的进步；它没有提供疾病过程的全面总结或手术指征的综述，这些可在AAES指南或美国国立卫生研究院原发性甲状旁腺功能亢进研讨会上找到。
